Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11266015 | 0.91 | MAOA (0.43) | MAOBMAOACYP2D6MEN1RECQL | |
| SCHEMBL8945898 | 0.90 | CYP19A1 (0.35) | MAOBMAOAGAACYP2D6MEN1 | |
| SCHEMBL9583012 | 0.88 | MEN1 (0.39) | CHRNA7MEN1RECQLKMT2AKDM4E | |
| SCHEMBL9582304 | 0.88 | MAOB (0.44) | MAOBMAOAGAAKDM4E | |
| SCHEMBL11282542 | 0.88 | MAOB (0.44) | MAOBMAOAMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL9583083 | 0.87 | MAOB (0.43) | MAOBMAOAKDM4E | |
| SCHEMBL9582495 | 0.86 | ALDH1A1 (0.41) | MAOBMAOAGAAMEN1RECQL | |
| SCHEMBL8945889 | 0.86 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL9582567 | 0.85 | HTR2A (0.38) | — | |
| SCHEMBL9582361 | 0.83 | MAOB (0.42) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| CN-102143961-A | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2011-08-03 | — | — | CN | claimed |
| EP-2310386-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2011-04-20 | — | — | EP | claimed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1687000-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| WO-2005102366-A2 | LITHIUM COMBINATIONS, AND USES RELATED THERETO | SATOW PHILIP MAXWELL (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NOVEN THERAPEUTICS, LLC | 2005-10-20 | — | — | US | claimed |
| WO-2005048999-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-5489681-A | Method for the preparation of 4-phenyl-1,3-benzodiazepins | HOESCHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | claimed |
| US-4461728-A | Preparation of 4-phenyl-1,3-benzodiazepins | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1984-07-24 | — | — | US | claimed |
| EP-0009800-B1 | 4-PHENYL-1,3-BENZODIAZEPINES, METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE COMPOUNDS FOR USE AS MEDICAMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-23 | — | — | EP | claimed |
| US-4309424-A | 4-Phenyl-1,3-benzodiazepines | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1982-01-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | CHRNB2 239/4885CHRNB4 231/4885CHRNA3 154/4885 |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NPY4R, ADRA1D, HTR4 | CHRNB2 159/4885CHRNB4 44/4885CHRNA3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.